title: Prophylaxis against venous thromboembolism after arthroplasty: establishing value requires more than one perspective. Commentary on an article by John T. Schousboe, MD, PhD, and Gregory A. Brown, MD, PhD: "Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty".
authors.affiliation: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
authors.forename: Adolph J
authors.initials: AJ
authors.lastname: Yates
mesh_terms: D019643:Arthroplasty, Replacement / Q000191:economics*; D001241:Aspirin / Q000191:economics*; D005260:Female; D005343:Fibrinolytic Agents / Q000191:economics*; D006495:Heparin, Low-Molecular-Weight / Q000191:economics*; D006801:Humans; D008297:Male; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D001241:Aspirin